Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study.
Journal
The pharmacogenomics journal
ISSN: 1473-1150
Titre abrégé: Pharmacogenomics J
Pays: United States
ID NLM: 101083949
Informations de publication
Date de publication:
18 Mar 2024
18 Mar 2024
Historique:
received:
05
02
2024
accepted:
05
03
2024
revised:
17
02
2024
medline:
19
3
2024
pubmed:
19
3
2024
entrez:
19
3
2024
Statut:
epublish
Résumé
Chronic kidney disease (CKD) is a global health issue. Kidney failure patients may undergo a kidney transplantation (KTX) and prescribed an immunosuppressant medication i.e., tacrolimus. Tacrolimus' efficacy and toxicity varies among patients. This study investigates the cost-utility of pharmacogenomics (PGx) guided tacrolimus treatment compared to the conventional approach in Austrian patients undergone KTX, participating in the PREPARE UPGx study. Treatment's effectiveness was determined by mean survival, and utility values were based on a Visual Analog Scale score. Incremental Cost-Effectiveness Ratio was also calculated. PGx-guided treatment arm was found to be cost-effective, resulting in reduced cost (3902 euros less), 6% less hospitalization days and lower risk of adverse drug events compared to the control arm. The PGx-guided arm showed a mean 0.900 QALYs (95% CI: 0.862-0.936) versus 0.851 QALYs (95% CI: 0.814-0.885) in the other arm. In conclusion, PGx-guided tacrolimus treatment represents a cost-saving option in the Austrian healthcare setting.
Identifiants
pubmed: 38499549
doi: 10.1038/s41397-024-00330-5
pii: 10.1038/s41397-024-00330-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10Subventions
Organisme : European Commission (EC)
ID : 668353
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, et al. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. NIHR J Libr. 2016;20:1–594.
Mudiayi D, Shojai S, Okpechi I, Christie EA, Wen K, Kamaleldin M, et al. Global estimates of capacity for kidney transplantation in world countries and regions. Transplantation. 2022;106:1113–22.
doi: 10.1097/TP.0000000000003943
pubmed: 34495014
pmcid: 9128615
Chemello C, Aguilera M, Cañadas Garre M, Calleja MA. Pharmacogenetics and pharmacogenomics of chronic kidney disease comorbidities and kidney transplantation. In: Barh D et al., editors. Omics for personalized medicine. 1st ed. India: Springer eBooks; 2013. p.801–18.
Boenink R, Kramer A, Tuinhout RE, Savoye E, Åsberg A, Idrizi A, et al. Trends in kidney transplantation rate across Europe: study from the ERA Registry. Nephrol Dial Transpl. 2023;38:1528–39.
doi: 10.1093/ndt/gfac333
McEwan P, Dixon S, Baboolal K, Conway P, Currie CJ. Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK. Pharmacoeconomics. 2006;24:67–79.
doi: 10.2165/00019053-200624010-00006
pubmed: 16445304
Glassock RJ, Warnock DG, Delanaye P. The global burden of chronic kidney disease: estimates, variability and pitfalls. Nat Rev Nephrol. 2017;13:104–14.
doi: 10.1038/nrneph.2016.163
pubmed: 27941934
Rancic N, Dragojevic-Simic V, Vavic N, Kovacevic A, Segrt Z, Djordjevic N. Economic evaluation of pharmacogenetic tests in patients subjected to renal transplantation: a review of literature. Front Public Health. 2016;4:189–97.
doi: 10.3389/fpubh.2016.00189
pubmed: 27630984
pmcid: 5005394
Provenzani A, Santeusanio A, Mathis E, Notarbartolo M, Labbozzetta M, Poma P, et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol. 2013;19:9156–73.
doi: 10.3748/wjg.v19.i48.9156
pubmed: 24409044
pmcid: 3882390
Turolo S, Edefonti A, Syren ML, Montini G. Pharmacogenomics of old and new immunosuppressive drugs for precision medicine in kidney transplantation. J Clin Med. 2023;12:4454–70.
doi: 10.3390/jcm12134454
pubmed: 37445489
pmcid: 10342352
Adams SM, Crisamore KR, Empey PE. Clinical pharmacogenomics: applications in nephrology. Clin J Am Soc Nephrol. 2018;13:1561–71.
doi: 10.2215/CJN.02730218
pubmed: 29793969
pmcid: 6218819
Nguyen TT, Pearson RA, Mohamed ME, Schladt DP, Berglund D, Rivers Z, et al. Pharmacogenomics in kidney transplant recipients and potential for integration into practice. J Clin Pharm Ther. 2020;45:1457–65.
doi: 10.1111/jcpt.13223
pubmed: 32662547
pmcid: 7719579
Crowley LE, Mekki M, Chand S. Biomarkers and pharmacogenomics in kidney transplantation. Mol Diagn Ther. 2018;22:537–50.
doi: 10.1007/s40291-018-0349-5
pubmed: 29971647
Chen L, Prasad GVR. CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment. Pharmgenomics Pers Med. 2018;11:23–33.
pubmed: 29563827
pmcid: 5846312
Lamba J, Hebert JM, Schuetz EG, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics. 2012;22:555–8.
doi: 10.1097/FPC.0b013e328351d47f
pubmed: 22407409
pmcid: 3738061
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401:347–56.
doi: 10.1016/S0140-6736(22)01841-4
pubmed: 36739136
van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharm Ther. 2017;101:341–58.
doi: 10.1002/cpt.602
Gordois AL, Toth PP, Quek RG, Proudfoot EM, Paoli CJ, Gandra SR. Productivity losses associated with cardiovascular disease: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2016;16:759–69.
doi: 10.1080/14737167.2016.1259571
pubmed: 27831848
Willan AR, Briggs A. Statistical analysis of cost‐effectiveness data. 1st ed. Canada: John Wiley & Sons Ltd; 2006.
doi: 10.1002/0470856289
General Hospital of Vienna, Clinical Insitute of Medical Analysis. Catalog of Parameters. 2023. https://www.akhwien.at/default.aspx?pid=3982 .
Chung R, Howard K, Craig JC, Chapman JR, Turner R, Wong G. Economic evaluations in kidney transplantation: frequency, characteristics, and quality-a systematic review. Transplantation. 2014;97:1027–33.
doi: 10.1097/TP.0000000000000079
pubmed: 24717216
Vannaprasaht S, Limwattananon C, Anutrakulchai S, Chan-On C. Effect of CYP3A5 genotype on hospitalization cost for kidney transplantation. Int J Clin Pharm. 2019;41:88–95.
doi: 10.1007/s11096-018-0750-5
pubmed: 30446894
Pasternak AL, Kidwell KM, Dempsey JM, Gersch CL, Pesch A, Sun Y, et al. Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant. Pharmacogenomics. 2019;20:421–32.
doi: 10.2217/pgs-2019-0002
pubmed: 30983501
Koufaki MI, Fragoulakis V, Díaz-Villamarín X, Karamperis K, Vozikis A, Swen JJ, et al. Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study. Hum Genomics. 2023;17:51–66.
doi: 10.1186/s40246-023-00495-3
pubmed: 37287029
pmcid: 10249170
Fragoulakis V, Roncato R, Bignucolo A, Patrinos GP, Toffoli G, Cecchin E, et al. Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study. Pharm Res. 2023;197:106949–58.
doi: 10.1016/j.phrs.2023.106949
Skokou M, Karamperis K, Koufaki MI, Tsermpini EE, Pandi MT, Siamoglou S, et al. Clinical implementation of preemptive pharmacogenomics in psychiatry. eBioMedicine. 2024;101:105009–23.
doi: 10.1016/j.ebiom.2024.105009
pubmed: 38364700
pmcid: 10879811
Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017;17:395–402.
doi: 10.1038/tpj.2017.21
pubmed: 28607506
pmcid: 5637230